Alnylam Pharmaceuticals, Inc.
ALNY
$251.56
$8.953.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 36.82% | 34.83% | 93.14% | 68.82% | 61.08% |
| Total Depreciation and Amortization | 4.84% | -40.57% | -42.45% | -41.80% | -36.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.34% | -1.52% | -8.37% | -10.56% | -19.78% |
| Change in Net Operating Assets | -473.87% | -791.82% | -200.13% | 135.80% | 261.06% |
| Cash from Operations | -107.98% | 2,766.45% | 178.75% | 135.25% | 119.24% |
| Capital Expenditure | 44.90% | 40.92% | 21.43% | 9.98% | 13.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.88% | -58.08% | -247.58% | -186.33% | -213.56% |
| Cash from Investing | 65.26% | -29.28% | -420.16% | -236.25% | -298.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 105.44% | 71.72% | -28.91% | -52.31% | -43.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -135.64% | -79.76% | -20.98% | -12.69% | -20.43% |
| Cash from Financing | 70.89% | 54.01% | -49.42% | -64.62% | -59.57% |
| Foreign Exchange rate Adjustments | -338.44% | 547.84% | -253.21% | -89.85% | 186.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 386.50% | 267.47% | 278.42% | -92.54% | -215.66% |